ALERT

Due to the overwhelming surge in COVID-19 cases and the strain it has placed on health care capacity in the communities we serve, the Idaho Department of Health and Welfare has activated crisis standards of care statewide. We are open and available to see patients, but you may experience delays at our ERs, hospitals, and clinics. We appreciate your patience. Access more info on COVID testing, vaccination, visitor policy, hospitalization data, and FAQs.

toggle mobile menu Menu
toggle search menu

Site Navigation

Supplemental

Menu

Retroperitoneal Lymph Node Dissection for Testicular Cancer

Retroperitoneal Lymph Node Dissection for Testicular Cancer

Surgery Overview

Retroperitoneal lymph node dissection (RPLND) is surgery often used to treat testicular cancer. It is done to remove lymph nodes that may be cancerous from the lower back and pelvis.

During the early phases of stage I nonseminoma testicular cancer, it can be very difficult to tell whether these lymph nodes are cancerous without surgically removing them first. For this reason, RPLND may be done even though there is no sign that the cancer has spread (metastasized) beyond the testes.

For many men, the greatest risk associated with RPLND may be sexual side effects. Besides the risks related to any major surgery, RPLND also may lead to a condition known as retrograde ejaculation as a result of nerve damage caused by the surgery. In retrograde ejaculation, the semen flows from the prostate gland into the bladder rather than through the penis and outside the body, resulting in infertility. Men who suffer from retrograde ejaculation typically do not have erection problems or difficulty enjoying sex.

Nerve-sparing surgery techniques can prevent retrograde ejaculation in most men who have this surgery. footnote 1

Try to find an experienced surgeon and a medical center where many surgeries are done for your kind of cancer. Experience can make a big difference. You will likely have fewer side effects, and you'll recover more quickly.

Related Information

References

Citations

  1. National Comprehensive Cancer Network (2012). Testicular cancer. NCCN Clinical Practice Guidelines in Oncology, version 1.2012. Available online: http://www.nccn.org/professionals/physician_gls/PDF/testicular.pdf.

Credits

Current as of: October 28, 2020

Author: Healthwise Staff
Medical Review:
E. Gregory Thompson MD - Internal Medicine
Kathleen Romito MD - Family Medicine
Christopher G. Wood MD, FACS - Urology, Oncology

This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. Healthwise is a URAC accredited health web site content provider. Privacy Policy. How this information was developed to help you make better health decisions.

© 1995-2015 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.